Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer

Approximately 25% of patients with ovarian cancer harbor a pathogenic BRCA1/2 mutation that has been associated with favorable responses for targeted therapy with poly (ADP-ribose) polymerase 1 (PARP1) inhibitors compared to wild-type individuals. The overall frequency of germline and somatic BRCA1/...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Ratajska, Magdalena, Koczkowska, Magdalena, Żuk, Monika, Gorczyński, Adam, Kuźniacka, Alina, Stukan, Maciej, Biernat, Wojciech, Limon, Janusz, Wasąg, Bartosz
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5731877/
https://ncbi.nlm.nih.gov/pubmed/29254167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20722
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares